Scarica l'app Stockscreener
5.42
1.69%
0.09
Dopo l'orario di chiusura:
5.38
-0.04
-0.74%
Sagimet Biosciences Inc Borsa (SGMT) Ultime notizie
Sagimet planning Phase 3 trials of denifanstat in MASH, MASLD - Liver Disease News
HC Wainwright Reaffirms "Buy" Rating for Sagimet Biosciences (NASDAQ:SGMT) - MarketBeat
Sagimet’s denifanstat enters Phase III trials for MASH treatment - Yahoo Finance
Sagimet Biosciences Announces Successful Completion of - GlobeNewswire
Sagimet Biosciences Announces Successful Completion of End-Of-Phase 2 Interactions with Fda on the Development of Denifanstat for Mash - Marketscreener.com
(SGMT) Technical Data - Stock Traders Daily
Sagimet Biosciences Inc. (NASDAQ:SGMT) Short Interest Update - MarketBeat
Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat - Seeking Alpha
(SGMT) Investment Analysis and Advice - Stock Traders Daily
There is no way Sagimet Biosciences Inc (SGMT) can keep these numbers up - SETE News
Market Highlights: Sagimet Biosciences Inc (SGMT) Ends on a Low Note at 5.13 - The Dwinnex
Sagimet Biosciences Announces Upcoming Presentations at AASLDThe Liver Meeting® 2024 - GlobeNewswire
How to interpret Sagimet Biosciences Inc (SGMT)’s stock chart patterns - US Post News
Sagimet Biosciences Inc’s Shares Reel: 42.19% Quarterly Revenue Decline Amid 167.12M Market Cap - The InvestChronicle
SGMT (Sagimet Biosciences Inc) may reap gains as insiders became active recently - Knox Daily
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in the Lancet Gastroenterology and Hepatology - Marketscreener.com
Sagimet Gains on Latest Numbers - Baystreet.ca
Sagimet's denifanstat shows promise in Phase 2b MASH trial - Investing.com
Sagimet's denifanstat shows promise in Phase 2b MASH trial By Investing.com - Investing.com UK
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial - The Bakersfield Californian
Sagimet Biosciences Announces Publication of Results from - GlobeNewswire
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology - StockTitan
Sagimet Biosciences Inc (SGMT) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Sagimet Biosciences Inc [SGMT] Shares Fall Approximately -47.47% Over the Year - Knox Daily
Financial Metrics Check: Sagimet Biosciences Inc (SGMT)’s Ratios for Trailing Twelve Months - The Dwinnex
How does Sagimet Biosciences Inc (SGMT) change from a tortoise to a hare? - SETE News
Sagimet Biosciences Inc. (NASDAQ:SGMT) Shares Sold by Renaissance Technologies LLC - MarketBeat
SGMT’s price-to-sales ratio: A comparative analysis with its peers - US Post News
Sagimet Biosciences Inc (SGMT) gets rating Downgrade from Goldman - Knox Daily
Leerink sees Sagimet stock as key NASH play with compelling Phase 3 outlook - Investing.com
Market Insights: Sagimet Biosciences Inc (SGMT)’s Notable Gain of 21.18, Closing at 4.12 - The Dwinnex
A new trading data show Sagimet Biosciences Inc (SGMT) is showing positive returns. - SETE News
Sagimet Biosciences Inc. Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Asc40 - Marketscreener.com
Analyze Sagimet Biosciences Inc (NASDAQ: SGMT) Before Investing. - Stocks Register
Sagimet Biosciences (NASDAQ:SGMT) Earns "Buy" Rating from HC Wainwright - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Earns “Buy” Rating from HC Wainwright - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Position Reduced by Point72 Asset Management L.P. - MarketBeat
Leerink maintains Sagimet Biosciences shares at Outperform rating By Investing.com - Investing.com Canada
Leerink maintains Sagimet Biosciences shares at Outperform rating - Investing.com
The Psychology of Sagimet Biosciences Inc Inc. (SGMT) Price Performance: Understanding Market Sentiment - The InvestChronicle
Sagimet (SGMT) Shares Surge After An FDA Grant - Stocks Telegraph
Sagimet Shares Rise Premarket on FDA Breakthrough Designation - Marketscreener.com
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH - GlobeNewswire
Sagimet Biosciences Inc. Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH - Marketscreener.com
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Sagimet Biosciences to Present at the H.C. Wainwright - GlobeNewswire
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Sagimet Biosciences' SWOT analysis: promising NASH drug faces funding hurdles - Investing.com India
Victory Capital Management Inc. Purchases 25,480 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Examining the Potential Price Growth of Surgery Partners Inc (SGRY) - Knox Daily
Esperion Therapeutics exec sells over $4,600 in stock - Investing.com
SEGRO (LON:SGRO) Reaches New 1-Year Low at $8.89 - Defense World
Surgery Partners Inc (SGRY) stock on the rise: An overview - US Post News
Bokf Na Purchases Shares of 11,905 Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
BofA Securities Downgrades Esperion Therapeutics Inc. (ESPR) to an Underperform from a Neutral - Knox Daily
Surgery Partners Inc (SGRY) is looking forward to a strong quarter - SETE News
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5% - MarketBeat
5.11%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):